CLINICAL_TRIALS
trial_result
· 2012-01-24
Clinical Trial Update: COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial [Phase 3]
Summary
Phase 3 COMFORT-I trial evaluating the oral JAK inhibitor ruxolitinib for myelofibrosis completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 3 | Status: COMPLETED | Results posted: 2012-01-24